Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 55 for your search:
Cancer Type:
Myeloproliferative disorders (incl. CML)
Stage/Subtype of Cancer:
polycythemia vera
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
2.
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-05011-L
, OHSU-210, NCT00245037
3.
Cyclophosphamide and Busulfan Followed By Donor Stem Cell Transplant in Treating Patients with Myelofibrosis
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-2130.00
, 6447, NCT00445744
4.
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PDX-009
, NCT00481871
5.
Chemotherapy, Donor Stem Cell Transplant, and Graft-Versus-Host Disease Prevention in Treating Patients With Advanced Hematologic Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0195
, 07-C-0195, NCT00520130
6.
Clofarabine, Melphalan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
NCI
Protocol IDs:
UCCRC-14341B
, 14341B, UCCRC-05-155, NCT00572546
7.
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
8.
Monoclonal Antibody Therapy, Fludarabine, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
9.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
10.
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
VGFT-ST-0708
, TCD10767, NCT00794417
11.
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
19 to 75
Sponsor:
NCI
Protocol IDs:
UNMC-16407
, 164-07, NCT00816413
12.
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
9090-03
, NCT00858572
13.
Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
8 to 80
Sponsor:
NHLBI
Protocol IDs:
NHLBI-99-H-0050
, NCT00003838
14.
Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
NCI-04-C-0055
, NCT00077480
15.
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1898.00
, 5788, NCT00089011
16.
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 70 years
Sponsor:
NCI
Protocol IDs:
JHOC-J0457
, JHOC-04072704, NCT00134004
17.
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
NCI
Protocol IDs:
UCSF-02257
, UCSF-2214, UCSF-H24045-22163-04, NCT00301912
18.
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0638
, J0638, 7704, NCI-7704, NCT00381550
19.
Fludarabine and Total-Body Irradiation Followed By a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2056.00
, 6171, NCT00397813
20.
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
10 to 75
Sponsor:
NHLBI
Protocol IDs:
NHLBI-06-H-0248
, NHLBI-IDE-13058, NCT00398346
21.
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years old and under
Sponsor:
NCI
Protocol IDs:
CCCWFU-29506
, CCCWFU 29506, NCT00453206, CCCWFU-IRB00001366
22.
Laboratory-Treated T Lymphocytes in Preventing Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Stem Cell Transplant for Hematologic Cancer or Other Disease
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NHLBI
Protocol IDs:
NHLBI-07-H-0136
, 07-H-0136
23.
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0788
, MC0788, NCT00630994
24.
A Phase II Study of Umbilical Cord Blood Transplantation
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
UCBT001
, NCT00676806
25.
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
11300A
, NCT00683046
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
